The EMA's Committee for Medicinal Products for Human Use (CHMP) has recommended the licensing of the adapted (i.e. updated) Spikevax vaccine that targets, in addition to the original SARS-CoV-2 strain, the BA.4 and BA.5 sub-variants of the Omicron variant.
The Spikevax bivalent Original/Omicron BA.4-5 adapted vaccine is recommended for adults and children aged 12 years and older who have already received the original COVID-19 vaccination regimen. A custom Spikevax vaccine targeting Omicron BA.1 and the original virus strain was licensed in September 2022.
The vaccines are tailored to better address circulating variants of the SARS-CoV-2 virus. They are expected to broaden protection against different variants and help maintain optimal levels of protection against COVID-19 as the virus evolves.
Evidence supporting the use of Spikevax bivalent Original/Omicron BA.4-5
In its decision to recommend the licensing of Spikevax bivalent Original/Omicron BA.4-5, the CHMP took into account all available data on Spikevax and the recently approved adapted Spikevax bivalent Original/Omicron BA.1In addition to the fact that they contain mRNA that matches different, but closely related, Omicron sub-variants, both adapted vaccines have the same composition.
One study found that a booster dose of Spikevax bivalent Original/Omicron BA.1 induced a stronger immune response against the original SARS-CoV-2 strain and the Omicron BA.1 sub- variant.
A study found that a booster dose of Spikevax bivalent Original/Omicron BA.1 induced a stronger immune response against the original SARS-CoV-2 strain and the Omicron BA.1 sub- variant. than a booster dose of the original licensed Spikevax vaccine.
The CHMP opinion on Spikevax bivalent Original/Omicron BA.4-5 is also based on data on its quality and manufacturing process, which confirmed that it meets EU quality standards. In addition, non-clinical laboratory data show that the adapted vaccine is able to induce an adequate immune response.
Based on all these data and the similar composition of the adapted vaccines, the CHMP concluded that Spikevax bivalent Original/Omicron BA.4-5 is expected to be more effective than the original authorised vaccine in triggering an immune response against BA.4 and BA.5 sub-variants. The safety profile of the vaccine is expected to be comparable to that of Spikevax bivalent Original/Omicron BA.1 and the original Spikevax, for which a large amount of data is available.
The CHMP opinion on Spikevax bivalent Original/Omicron BA.4-5 will now be sent to the European Commission, which will adopt a final decision.
Use of COVID-19 vaccines
Together with the adapted Spikevax bivalent Original/Omicron BA.1 this new adapted vaccine is expected to help maintain optimal protection against COVID-19 as the virus evolves.
The EU strategy is to have a wide range of adapted vaccines targeting different variants of the SARS-CoV-2 virus so that Member States have several options to meet their needs when planning their vaccination campaigns. This is a key element of the overall pandemic response strategy, as it is not possible to predict how the virus will evolve in the future and which variants will be released this winter.
Like all currently licensed COVID-19 vaccines, the prototype Spikevax vaccine, continues to be effective in preventing severe disease, hospitalisation and death associated with COVID-19 and will continue to be used as part of EU vaccination campaigns, particularly for initial vaccination schedules.
National authorities in EU Member States will determine who should receive which vaccines and when, taking into account factors such as infection and hospitalisation rates, risk to vulnerable groups, vaccine coverage and vaccine availability.
How Spikevax bivalent Original/Omicron BA.4-5
Adapted vaccines work in the same way as the original vaccines. They work by preparing the body to defend itself against COVID-19 disease.
Spikevax bivalent Original/Omicron BA.4-5 contains molecules called mRNA that are instructed to create the spike proteins of the original SARS-CoV-2 virus strain and the BA.4 and BA.5 sub-variants of Omicron. The spike protein is a protein on the surface of the virus that the virus needs to enter body cells and may differ between virus variants. The spike proteins in the BA.4 and BA.5 sub-variants of Omicron are identical. By tailoring the vaccines, the goal is to broaden protection against different variants.
When a person is given the vaccine, some of their cells will read the mRNA instructions and temporarily produce the spike proteins. Subsequently, the person's immune system will recognise these proteins as foreign and activate natural defences - antibodies and T cells - against them.
If, later, the vaccinated person comes into contact with the virus, the immune system will recognise the spike proteins on its surface and be ready to attack the virus. The immune system's antibodies and cells can protect against COVID-19 disease by killing the virus through synergy, preventing it from entering the body's cells and destroying infected cells.
More about the process
The company responsible for marketing the Spikevax vaccine has submitted an application (also known as a variation application) to vary the existing marketing authorisation for the licensed Spikevax vaccine to include the use of the adapted vaccine targeting the Omicron BA sub-variants.4 and BA.5 in addition to the original SARS-CoV-2 strain. The evaluation was carried out by the EMA's Committee for Medicinal Products for Human Use (CHMP), which is responsible for questions on medicinal products for human use. The opinion of the CHMP has been forwarded to the European Commission, which will adopt a final legally binding decision applicable in all EU Member States.
(AF)
Contents of this article including associated images are owned by PIO
Views & opinions expressed are those of the author and/or PIO
Source